Sotera Health [SHC] vs Thermo Fisher [TMO] Detailed Stock Comparison
Sotera Health
NASDAQ
Loading...
Thermo Fisher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sotera Health wins in 7 metrics, Thermo Fisher wins in 12 metrics, with 0 ties. Thermo Fisher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sotera Health | Thermo Fisher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 181.89 | 28.50 | Thermo Fisher |
| Price-to-Book Ratio | 9.09 | 3.68 | Thermo Fisher |
| Debt-to-Equity Ratio | 460.02 | 69.62 | Thermo Fisher |
| PEG Ratio | 20.21 | 5.02 | Thermo Fisher |
| EV/EBITDA | 12.70 | 19.87 | Sotera Health |
| Profit Margin (TTM) | 2.14% | 15.24% | Thermo Fisher |
| Operating Margin (TTM) | 35.34% | 17.84% | Sotera Health |
| EBITDA Margin (TTM) | 35.34% | 17.84% | Sotera Health |
| Return on Equity | 5.14% | 13.42% | Thermo Fisher |
| Return on Assets (TTM) | 7.24% | 4.97% | Sotera Health |
| Free Cash Flow (TTM) | $45.09M | $7.27B | Thermo Fisher |
| Dividend Yield | N/A | 0.31% | N/A |
| 1-Year Return | 6.02% | -19.89% | Sotera Health |
| Price-to-Sales Ratio (TTM) | 4.13 | 4.31 | Sotera Health |
| Enterprise Value | $6.67B | $214.99B | Thermo Fisher |
| EV/Revenue Ratio | 5.93 | 4.98 | Thermo Fisher |
| Gross Profit Margin (TTM) | 56.61% | 40.61% | Sotera Health |
| Revenue per Share (TTM) | $4 | $114 | Thermo Fisher |
| Earnings per Share (Diluted) | $0.09 | $17.29 | Thermo Fisher |
| Beta (Stock Volatility) | 1.81 | 0.75 | Thermo Fisher |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Sotera Health vs Thermo Fisher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sotera Health | 1.05% | -0.37% | 34.84% | 32.23% | 31.28% | 20.19% |
| Thermo Fisher | 0.61% | -1.45% | 2.19% | 22.04% | -6.85% | -5.71% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sotera Health | 6.02% | -3.25% | -34.78% | -34.78% | -34.78% | -34.78% |
| Thermo Fisher | -19.89% | -9.35% | 20.18% | 306.64% | 990.33% | 1,676.21% |
Performance & Financial Health Analysis: Sotera Health vs Thermo Fisher
| Metric | SHC | TMO |
|---|---|---|
| Market Information | ||
| Market Cap | $3.31B | $197.55B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 1,471,790 | 1,659,670 |
| 90 Day Avg. Volume | 1,533,057 | 2,593,033 |
| Last Close | $16.37 | $492.72 |
| 52 Week Range | $9.53 - $17.08 | $385.46 - $627.88 |
| % from 52W High | -4.16% | -21.53% |
| All-Time High | $30.38 (Mar 15, 2021) | $672.34 (Dec 27, 2021) |
| % from All-Time High | -46.12% | -26.72% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | 0.03% |
| Quarterly Earnings Growth | -0.09% | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.15% |
| Operating Margin (TTM) | 0.35% | 0.18% |
| Return on Equity (TTM) | 0.05% | 0.13% |
| Debt to Equity (MRQ) | 460.02 | 69.62 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.80 | $133.77 |
| Cash per Share (MRQ) | $1.17 | $16.92 |
| Operating Cash Flow (TTM) | $266.11M | $7.58B |
| Levered Free Cash Flow (TTM) | $218.81M | $5.18B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.31% |
| Last 12-Month Dividend | N/A | $1.21 |
Valuation & Enterprise Metrics Analysis: Sotera Health vs Thermo Fisher
| Metric | SHC | TMO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 181.89 | 28.50 |
| Forward P/E | 20.21 | 20.98 |
| PEG Ratio | 20.21 | 5.02 |
| Price to Sales (TTM) | 4.13 | 4.31 |
| Price to Book (MRQ) | 9.09 | 3.68 |
| Market Capitalization | ||
| Market Capitalization | $3.31B | $197.55B |
| Enterprise Value | $6.67B | $214.99B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.93 | 4.98 |
| Enterprise to EBITDA | 12.70 | 19.87 |
| Risk & Other Metrics | ||
| Beta | 1.81 | 0.75 |
| Book Value per Share (MRQ) | $1.80 | $133.77 |
Financial Statements Comparison: Sotera Health vs Thermo Fisher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SHC | TMO |
|---|---|---|
| Revenue/Sales | $254.52M | $10.36B |
| Cost of Goods Sold | $119.09M | $6.13B |
| Gross Profit | $135.43M | $4.24B |
| Research & Development | N/A | $342.00M |
| Operating Income (EBIT) | $57.04M | $1.82B |
| EBITDA | $98.09M | $2.73B |
| Pre-Tax Income | $-14.82M | $1.62B |
| Income Tax | $-1.56M | $95.00M |
| Net Income (Profit) | $-13.26M | $1.51B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SHC | TMO |
|---|---|---|
| Cash & Equivalents | $304.39M | $4.13B |
| Total Current Assets | $554.99M | $23.38B |
| Total Current Liabilities | $225.99M | $13.17B |
| Long-Term Debt | $2.32B | $31.37B |
| Total Shareholders Equity | $414.09M | $49.49B |
| Retained Earnings | $-623.30M | $54.45B |
| Property, Plant & Equipment | $1.07B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SHC | TMO |
|---|---|---|
| Operating Cash Flow | $58.73M | $2.15B |
| Capital Expenditures | $-19.92M | $-350.00M |
| Free Cash Flow | $35.60M | $361.00M |
| Debt Repayment | $-3.77M | $-838.00M |
| Common Stock Repurchase | N/A | $-2.00B |
Short Interest & Institutional Ownership Analysis
| Metric | SHC | TMO |
|---|---|---|
| Shares Short | 13.75M | 3.82M |
| Short Ratio | 9.40 | 1.29 |
| Short % of Float | 0.09% | 0.01% |
| Average Daily Volume (10 Day) | 1,471,790 | 1,659,670 |
| Average Daily Volume (90 Day) | 1,533,057 | 2,593,033 |
| Shares Outstanding | 283.47M | 380.77M |
| Float Shares | 134.03M | 376.76M |
| % Held by Insiders | 0.02% | 0.00% |
| % Held by Institutions | 0.96% | 0.92% |
Dividend Analysis & Yield Comparison: Sotera Health vs Thermo Fisher
| Metric | SHC | TMO |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.21 |
| Last 12-Month Dividend Yield | N/A | 0.31% |
| 3-Year Avg Annual Dividend | N/A | $1.33 |
| 3-Year Avg Dividend Yield | N/A | 0.07% |
| 3-Year Total Dividends | N/A | $3.99 |
| Ex-Dividend Date | N/A | Mar 14, 2025 |